Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or (I.R.S. Employer Identification Number) 9804 Medical Center Drive Rockville, MD 20850 (240) 552-8181 (Address of principal executive offices and Zip Code, and telephone number, including area code) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ...

REGENXBIO Inc. (NASDAQ:RGNX) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Patrick Christmas - Chief Legal Officer Vit Vasista - Chief Financial Officer Ken Mills - President & Chief Executive Officer Steve Pakola - Chief Medical Officer Lejla Vajzovic - Associate Professor, Ophthalmology; and Director, Duke Vitreoretinal Fellowship Program and Lead Investigator Peter Kaiser - Director, Center for Ocular Research and Evaluation, Cole Eye Institute, Cleveland Clinic. Confe ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number 001-37553 REGENXBIO Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-1851754 (S ...

REGENXBIO Inc. (NASDAQ:RGNX) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Vit Vasista - Chief Financial Officer Ken Mills - President & Chief Executive Officer Steve Pakola - Chief Medical Officer Conference Call Participants Dane Leone - Raymond James Ellie Merle - UBS Lisa Walter - RBC Capital Markets Andreas Argyrides - Wedbush Securities Mani Foroohar - SVB Securities Operator Good day, ladies and gentlemen. Thank you for standing by. Welcome to the Second Quarter 2022 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number 001-37553 REGENXBIO Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-1851754 (State ...

Corporate Presentation 1 Leader in AAV Gene Therapy 7 | 18 | 2022 Forward-looking statements This presentation includes "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements express a belief, expectation or intention and are generally accompanied by words that convey projected future events or outcomes such as "believe," "may," "will," "estimate," "continue," "anticipate, ...

REGENXBIO Inc. (NASDAQ:RGNX) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Patrick Christmas - Chief Legal Officer Ken Mills - President and CEO Steve Pakola - Chief Medical Officer Vit Vasista - CFO Conference Call Participants Andreas Argyrides - Wedbush Securities Operator Good day and thank you for standing by. Welcome to the Q1 2022 REGENXBIO Inc. Earnings Conference Call. At this time, all participants are in listen-only mode. After the speakers’ presentation, there wil ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number 001-37553 REGENXBIO Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-1851754 (State ...

REGENXBIO Inc. (NASDAQ:RGNX) Q4 2021 Earnings Conference Call March 1, 2022 4:30 PM ET Company Participants Patrick Christmas – Chief Legal Officer Ken Mills – President and Chief Executive Officer Steve Pakola – Chief Medical Officer Vit Vasista – Chief Financial Officer Conference Call Participants Alec Stranahan – Bank of America Dane Leone – Raymond James Mani Foroohar – SVB Leerink Andreas Argyrides – Wedbush Operator Thank you for joining Q4 2021 REGENXBIO Inc. Earnings Conference Call. At this time, ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37553 REGENXBIO Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorp ...